Isabl is a cutting-edge platform designed to revolutionize cancer diagnostics by providing comprehensive analysis of the entire tumor genome and transcriptome. Unlike traditional panel-based tests that examine only a fraction of the genome, Isabl's technology evaluates 100% of the cancer DNA and RNA, uncovering all cancer-associated mutations in each sample. This holistic approach enhances biomarker discovery, offering more precise diagnoses and personalized treatment options for patients across various cancer types.
Key Features and Functionality:
- Comprehensive Genomic Analysis: Isabl's GxT platform integrates data from the entire tumor genome and transcriptome into a single diagnostic workflow, eliminating the limitations of targeted sequencing.
- Advanced Bioinformatics Applications: The platform supports assembly-aware bioinformatics applications, ensuring analyses are tailored to specific reference genomes.
- User-Friendly Interfaces: Isabl offers a web application for managing operations metadata and visualizing analysis results, alongside a command-line interface and software development kit for efficient data management and processing.
- Operational Automations: The system automates data import and analysis status changes, streamlining workflows and reducing manual intervention.
Primary Value and Solutions Provided:
Isabl addresses the limitations of existing diagnostic tests by offering a more comprehensive and accurate genomic analysis. By detecting all cancer-associated mutations, including those missed by standard assays, Isabl enables better risk stratification, informed treatment planning, and improved patient outcomes. Its integration of advanced bioinformatics tools and user-friendly interfaces simplifies the diagnostic process, making full genome testing accessible and practical for clinical use. Ultimately, Isabl empowers healthcare providers with the insights needed to deliver truly personalized cancer care.
